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ABSTRACT
The TP63 gene codes for two major isoform types, TAp63 and ΔNp63, with 
probable opposite roles in tumorigenesis. The ΔNp63α protein is frequently amplified 
and overexpressed in different epithelial tumors. Accordingly, it has been considered 
a potential oncogene. Nonetheless, a possible metastatic suppressor activity has also 
been suggested based on the experimental observation that its expression is reduced 
or even absent in advanced invasive tumors. Such metastatic suppressor activities are 
often related to tumors bearing point mutated TP53 gene. However, its potential roles 
in TP53-deficient tumors are poorly characterized. Here we show that in spontaneous 
tumors, induced by the epidermal-specific Trp53 ablation, the reduction of ΔNp63 
expression is an early event, whereas it is re-expressed in the lung metastatic 
lesions. Using knock down and ectopic expression approaches, we show that ΔNp63 
expression opposes the epithelial-mesenchymal transition and reduces the metastatic 
potential of the cells. This process occurs through the modulation of ΔNp63-dependent 
downstream targets (including transcription factors and microRNAs) likely to play 
metastatic roles. Further, ΔNp63 also favors the expression of factors involved in iPS 
reprogramming, thus suggesting that it can also modulate specific stem cell traits in 
mouse epidermal tumor cells. Overall, our data assign antimetastatic roles to ΔNp63 
in the context of p53 deficiency and epidermis.
INTRODUCTION
The TP63 gene forms, together with TP53 and 
TP73, the so-called p53 family. These genes produce 
multiple isoforms due to alternative splicing and 
alternative promoter usage [1]. The resulting proteins 
exert specific roles in development, differentiation and 
cancer progression [2]. This last aspect is highlighted 
by the extremely frequent mutations affecting the TP53 
gene in multiple human tumors, which in general are 
associated with increased malignancy and poor clinical 
outcome [3–5]. However, the roles of the other p53 family 
members in the context of cancer are less understood. 
This could be attributed to the differential expression of 
multiple isoforms with distinct properties. In the case 
of TP63, by the use of alternative promoters, two major 
isoform types are transcribed, named TAp63 and ΔNp63, 
with different and often opposing functional properties 
[6]. TAp63 can induce cell cycle arrest and apoptosis and 
participates in the DNA damage response [7, 8], functions 
commonly attributed to the p53 family. ΔNp63 is primarily 
expressed in the basal layer of most stratified epithelia and 
exerts essential functions in epithelial development and 
differentiation [9, 10]. In the context of cancer, the roles 
of these isoforms and their possible crosstalk with p53 
are still partially obscure. With few exceptions, mutations 
of the TP63 gene are rare in human malignancies, 
suggesting that it is not a canonical tumor suppressor. On 
the contrary, several human tumors display overexpression 
and also amplification of this gene, suggesting a potential 
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oncogenic role [11]. This last aspect is particularly 
relevant for the ΔNp63α isoform, which is specifically 
amplified and overexpressed in multiple stratified 
epithelia-derived tumors [12], promotes the activation of 
stratified-epithelia relevant oncogenic pathways [13], can 
mediate resistance to chemotherapy [14], and overcome 
the oncogene-induced senescence [15]. Nonetheless, 
in some aggressive metastatic epithelial tumors the 
expression of ΔNp63 is reduced and often lost, suggesting 
potential roles as metastasis suppressor [16–21]. This is in 
agreement with the observed ability of ΔNp63 to bind and 
modulate the expression of a variety of genes, including 
transcription factors, adhesion and signaling molecules, 
and also several miRNAs [14, 20, 22–25]. In addition, 
these roles may also explain why the limited metastatic 
spreading of spontaneous tumors arising in Trp53−/− 
mice is significantly enhanced by simultaneous ablation 
of the Trp63 gene [26]. However, the potential opposite 
differences affecting the functional roles of TAp63 and 
ΔNp63 isoform types makes the possible contribution of 
these proteins a complex issue. Therefore, further research 
is clearly needed to ascertain the actual oncogenic and/or 
metastatic suppressor roles of ΔNp63 in order to consider 
possible targeted therapies.
The functional interaction between p53- and 
p63-dependent signaling pathways has remained 
poorly investigated until recently, when two new 
mechanisms have been described. These implicated the 
physical interaction between p63 and mutant p53 in the 
context of TGFβ signaling, leading to the inhibition of 
various genes involved in metastasis and whose expression 
is regulated by p63 [27, 28]. Although the possible 
differences affecting TAp63 and ΔNp63 isoform types in 
this context have not been completely elucidated, these 
findings reinforce a possible role of p63 as a metastasis 
suppressor and also may help to explain the gain of 
function of missense mutations of the TP53 gene and their 
involvement in the increased malignancy observed in 
human p53-mutant tumors [29–31]. Nevertheless, human 
tumors also frequently display absence of p53 expression 
due to deletion of the TP53 gene, and the occurrence of 
TP53 gene point mutations leading to premature stop 
codon generation. The potential roles of p63 in this context 
of p53 loss are almost completely unknown.
We have previously reported that the specific 
ablation of Trp53 in mouse stratified epithelia 
(hereafter Trp53ΔEpi mice) leads to spontaneous tumor 
development [32]. These tumors arise primarily in 
the epidermis and their onset is accelerated by the 
concomitant loss of other tumor suppressors such as Rb1 
and Pten [32, 33]. Importantly, the transcriptome analyses 
of these mouse tumors revealed massive overlapping 
with multiple human tumors characterized by poor 
prognosis, metastatic spreading and p53 mutation [34]. 
This overlap is not limited to human skin cancers, and 
includes multiple tumors of high clinical relevance arising 
in tissues such as breast and lung [35]. Interestingly, 
the transcriptome analysis also revealed a significant 
enrichment of stem cell-like signatures in these p53-
deficent tumors [34], which are also associated with the 
metastatic spreading of human tumors [36]. More recently 
we also demonstrated the high metastatic capacity of these 
Trp53ΔEpi tumors, and we characterized a role for specific 
miRNAs in this process through a possible modulation of 
the epithelial mesenchymal transition (EMT) signaling 
pathway [37]. EMT is a critical process during embryonic 
development and has also been recognized as a potential 
mechanism for carcinoma metastasis [38, 39]. During 
EMT, epithelial cells lose cell-to-cell adhesion and cell 
polarity to gain mesenchymal features, providing motility 
and invasiveness. This is accomplished by an intricate 
network of transcription factor activation, including 
TWIST, SNAIL, SLUG, ZEB1 and ZEB2 which are also 
under epigenetic regulation through various miRNAs 
[38, 40, 41]. Importantly, recent evidences also support 
a role for ΔNp63 modulating EMT [18, 19]. Here we 
report that spontaneous tumors arising in Trp53ΔEpi mice 
display early repression of ΔNp63 expression. Using 
overexpression and knock down approaches, we also 
observe that altered expression of ΔNp63 leads to the 
disturbed expression of various transcription factors and 
miRNAs involved in the acquisition of stem cell-like 
characteristics and in the EMT process.
RESULTS
Reduced ΔNp63 expression is an early event in 
Trp53ΔEpi spontaneous tumors
Immunohistochemical analyses revealed that the 
pattern of p63 expression in the skin of Trp53ΔEpi and 
Trp53ΔEpi;Rb1ΔEpi mice is undistinguishable from control wt 
mice (Fig. 1A, 1E), and remains expressed, mainly in the 
basal layer, in areas of epidermal dysplasia (Fig. 1B, 1E). 
However, its expression is drastically reduced in squamous 
cell carcinoma (SCC) (Fig. 1C, 1E) and almost completely 
absent in spindle cell carcinomas (SpCC) (Fig. 1D, 1E). 
Since the antibody used reacts with all p63 isoforms, we 
also performed a qRT-PCR analysis using primers specific 
for the ΔNp63 isoform. This revealed the systematic 
reduction of this isoform in mouse tumors (Fig. 1F). 
These findings were corroborated by western blot analyses 
(Fig. 1G), which also showed that ΔNp63α, the major 
isoform expressed in skin, is absent in most tumors, 
although some of them expressed p63 isoforms of lower 
molecular weight (indicated by arrow in Fig. 1G). We also 
studied the p63 expression in the spontaneous metastatic 
lesions arising in the lungs of Trp53ΔEpi or Trp53ΔEpi;Rb1ΔEpi 
mice. We found that these lesions display positive p63 
staining (Fig. 1H, H’), suggesting that the observed 
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Figure 1: ΔNp63 downregulation is an early event in spontaneous Trp53-deficient epidermal tumors. A–D. Representative 
examples of p63 expression in non lesional epidermis (A), dysplasia (B), moderately differentiated tumor (C) and undifferentiated 
tumor from Rb1ΔEpi;Trp53ΔEpi mice as assessed by immunohistochemistry. E–F. Summary of p63 expression in samples determined by 
immunohistochemistry (E) or qRT-PCR (F) G. Immunoblot of the quoted protein extracts showing the expression of p63 isoforms. Note 
the lack of ΔNp63α expression in tumors, regardless their genotype, and the presence of a fast migrating isoform in some of them (denoted 
by red arrow). H, H’. Representative examples of p63 expression in lung metastases. H’ is a high magnification of the area denoted in H 
covering the metastatic nodule. Bars = 150 μm
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reduction of ΔNp63α expression in the primary tumors is 
not attributable to gene loss or deletion, but rather to a 
transcriptional repression.
The expression of ΔNp63 opposes EMT in 
Trp53ΔEpi tumors
To study the functional consequences of the 
reduced p63 expression, we sought to express huΔNp63α 
in the 940 SpCC cells [37]. These cells were derived 
from a Trp53ΔEpi;Rb1ΔEpi mouse spontaneous primary 
tumor, which also showed lung metastasis [37]. 
Compared with COCA immortalized keratinocytes 
[42], the 940 cells are characterized by a spindle 
morphology (Supplementary Fig. 1A, 1B), absence 
of p53 and TAp73α expression, severe reduction of 
ΔNp63α expression, and increased expression of 
ΔNp73α (Supplementary Fig. 1C). In these cells, the 
pharmacological treatment to inhibit specific pathways 
that can mediate p63 repression leads to partial increase 
in ΔNp63 (Supplementary Fig. 1D). However, its levels 
never reached those observed in immortalized COCA 
keratinocytes (Supplementary Fig. 1D). Previous data 
also showed that 940 cells are highly metastatic when 
injected either subcutaneously or in the tail vein of 
immunocompromised mice [37], whereas COCA cells are 
not tumorigenic [42]. We used a lentiviral vector, which 
also expressed the EGFP protein, to ectopically express 
huΔNp63α, and transduced cells were sorted based on 
EGFP fluorescence. Compared to the control EGFP 
transduced cells (Fig. 2A, 2E), the majority of the 940 
cells transduced with huΔNp63α showed the expression of 
Figure 2: Expression of huΔNp63α in 940 cells ameliorates EMT process. A–D. Representative immunofluorescence images 
of 940 cells traduced with GFP (A, B) or ΔNp63α (C, D) showing the expression and localization of p63 (A, C) and E-Cadherin (B, D). 
E. Immunoblot of the quoted protein extracts showing the expression of p63, Snail and E-cadherin. Actin was used to normalize loading. 
F, G. Determination of migratory (F) and invasive (G) properties of 940 cells upon transduction with GFP or ΔNp63α coding lentiviruses. 
H, I. Determination of the expression of transcription factors (H) and miRNAs (I) involved in EMT processes as assessed by qRT-PCR 
analyses. Data came from at least quadruplicated experiments. *denotes p value < 0.05, **denotes p value < 0.01 Bars = 150 μm
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the transduced gene (Fig. 2C, 2E). Importantly, although 
no major changes in cell morphology were detected 
upon huΔNp63α expression (not shown), we observed a 
partial increase in E-cadherin expression, which was not 
properly localized at the cell-cell contacts (Fig. 2B, 2D, 
2E). Moreover, the expression of huΔNp63α produces a 
limited inhibition of the migratory (Fig. 2F) and invasive 
(Fig. 2G) characteristics of the 940 cells. The silencing of 
the Cdh1 gene (coding for E-cadherin) is an early marker 
and a prerequisite for the EMT process. This event is 
promoted by the concerted action of various transcription 
factors including Snail, FoxC2, Zeb1, Zeb2 and Twist1, 
which are also induced early in the spontaneous tumors 
arising in Trp53ΔEpi mice [37]. We observed that the 
expression of huΔNp63α in 940 cells induced a significant 
decrease in the expression of all these transcription factors 
that promote EMT (Fig. 2E, 2H). Remarkably, none of 
these genes have been identified as bound by p63 [20, 
22–25], suggesting that such reduction is not directly 
mediated by p63 binding to their respective promoters.
Several miRNA modulate the EMT process [40, 
43, 44] and are regulated by p53 and/or p63 [14, 24, 45]. 
These include miR21, miR200 family, miR34 family, 
miR130a, miR203, miR19a and miR205. We thus analyzed 
whether the expression of these miRNAs was affected 
by the ectopic expression of HuΔNp63α in 940 cells. 
We observed a significant reduction in the expression of 
miR21, miR34a, miR200c, miR203 and miR19a, whereas 
miR200a, miR200b and miR205 displayed increased 
expression in HuΔNp63α-expressing 940 cells (Fig. 2I). 
Importantly, the reduction of miR21, miR19a and miR203, 
and the increased expression of miR200a, miR200b and 
miR205 are compatible with a possible reduction in the 
metastatic potential of 940 cells upon ectopic expression 
of huΔNp63α, and may explain the indirect regulation of 
EMT-mediating transcription factors described above.
Collectively, these data indicate that p63 expression 
opposes EMT, probably through the indirect modulation 
of the expression of various transcription factors due to 
altered miRNA expression, but it is unable to completely 
reverse this process, as shown by the absence of significant 
changes in cell morphology and E cadherin localization.
ΔNp63 expression delays metastatic spreading
To ascertain whether the functional consequences 
of the deregulated expression of miRNAs and reduced 
expression of transcription factors induced by huΔNp63α 
cells may result in altered metastatic spreading of these 
cells, we subcutaneously injected control or huΔNp63α-
transduced cells in the flank of athymic (nu/nu) mice. 
We observed that mice developed tumors with similar 
incidence regardless the cells injected (Fig. 3A). Further, 
the spindle histology of the tumors was similar between 
control and huΔNp63α-transduced cells (not shown). 
However, the tumors generated by huΔNp63α-transduced 
cells displayed a partial delayed growth compared with 
the controls (Fig. 3B). In spite of this observation, the cell 
cycle profiles were similar in control and in huΔNp63α-
transduced cells (Supplementary Fig. 2A).
To monitor possible metastatic outgrowths, the 
cohort of mice was split into two subgroups. In one 
of them the lungs were analyzed immediately after 
sacrifice, whereas in the other the subcutaneous tumors 
were surgically removed, and mice were euthanized one 
month later. In the first group the huΔNp63α-transduced 
displayed reduced lung metastasis incidence (percentage 
of lung lobules bearing metastatic lesions) compared to 
control cells (Fig. 3C, C’, 3D), and also a reduced number 
of metastatic nodules (number of metastatic lesions per 
lung lobule) (Fig. 3C, C’, 3E), indicating that the forced 
expression of huΔNp63α caused a delayed metastatic 
spreading. However, these differences were not observed 
when the tumors were surgically removed and mice kept 
alive for further 30 days (Fig. 3F, 3G). Nonetheless, we 
observed that the number of cells expressing huΔNp63α 
in the subcutaneous tumors was very low (Fig. 4A, A’) 
compared with the parental cells injected (Fig. 2C). As 
expected, no p63 expression was observed in tumors 
produced by the injection of control EGFP-expressing 
cells (Fig. 4B, B’). To further support this finding, we 
performed qRT-PCR of huΔNp63α from transduced 
cells, subcutaneous tumors and lungs bearing metastatic 
nodules. We observed a significant reduction in tumors 
compared with cells, which is further reduced in the lungs 
(Fig. 4C).
The metastatic dissemination depends on various 
sequential events: invasion intravasation, survival in the 
blood stream, extravasation and colonization of the target 
organ. To study whether the last steps of the process 
were affected by huΔNp63α expression, control and 
huΔNp63α-transduced cells were injected in the tail vein 
of athymic (nu/nu) mice. Upon sacrifice we detected a 
reduced number of lung nodules in the case of huΔNp63α-
transduced cells compared to control cells (Fig. 5A, A’, 5C) 
in spite of similar metastatic incidence (Fig. 5B). The 
reduced lung colonization was further confirmed by 
measuring the lung area covered by nodules, which 
was also reduced in the case of huΔNp63α-transduced 
cells (Fig. 5D). Nonetheless, we also observed that the 
number of cells expressing huΔNp63α was severely low 
in the metastatic nodules (Fig. 5E), in agreement with the 
PCR observations (Fig. 4C). Collectively these findings 
indicated that huΔNp63α caused a partial inhibition of 
metastatic spreading. However, our data also suggested 
that huΔNp63α expression caused a potential growth 
disadvantage in vivo, and was probably silenced during 
tumor growth and metastatic spreading. This led to a 
reduced presence of cells expressing huΔNp63α in the 
tumors and metastases.
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Reduced ΔNp63 expression favors EMT
The above described results indicated that the 
forced expression of huΔNp63α in p53-deficient cells 
reduces metastatic behavior and the expression of genes 
and miRNAs that mediate EMT. To monitor whether 
the reduced expression of p63 facilitates these events, 
we used knock down approaches in PB keratinocytes. 
These cells were isolated from a chemically induced 
mouse papilloma and bear Trp53 mutations [46]. Upon 
subcutaneous injection they render mostly differentiated 
SCCs and no metastasis [47]. We used two different 
shRNA lentiviral constructs that significantly reduced the 
endogenous p63 expression as confirmed by immunoblot 
(Fig. 6A) and qPCR (Fig. 6B) affecting both ΔN and TA 
isoforms. Importantly, although TAp63 can be detected by 
qPCR (Fig. 6B), its levels are extremely low (not shown), 
thus suggesting that the possible changes observed 
Figure 3: Expression of huΔNp63α decreases spontaneous metastasis development. A. Tumor incidence upon subcutaneous 
injection of 940 cells upon transduction with GFP (black line) or ΔNp63α (red line) coding lentiviruses determined by Kaplan Meyer curves. 
P Value was determined by log rank test. B. Tumor growth of subcutaneously injected 940 (open squares) or huΔNp63α (blue squares) 
cells. P Value was determined by 2Way ANOVA followed by Bonferroni post-test. *denotes p value < 0.05, ****denotes p value < 0.0001. 
C, C’. Representative images of H&E stained lung lobule sections showing the presence of metastatic nodules (denoted by arrows) upon 
tumor induction by subcutaneous injection of 940 cells upon transduction with ΔNp63α (C) or GFP (C’) coding lentiviruses. Bar = 0.5 cm 
D, E. Summary of lung metastasis incidence (D) and number of metastatic nodules per lung lobule (E) observed in mice bearing 
subcutaneously injected with 940 or huΔNp63α cells and sacrificed one month after injection. F, G. Summary of lung metastasis incidence 
(D) and number of metastatic nodules per lung lobule (E) observed in mice one month after surgical removing the subcutaneous tumors 
produced by 940 or huΔNp63α 940 cells.
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(see below) are not primarily attributable to the decreased 
TAp63 levels. Immunofluorescence analysis corroborated 
the reduction of ΔNp63 expression (Fig. 6C, C’) and 
suggested a concomitant decrease in E-Cadherin in the 
p63 silenced cells (Fig. 6D, D’). Immunoblot and qPCR 
studies showed that the decreased ΔNp63 expression in PB 
cells was accompanied with a significant increase in Snail, 
Twist1, Zeb1 and FoxC2 expression, and confirmed the 
reduction of E-cadherin (Fig. 6E, 6F). In agreement, the 
reduced expression of p63 also accounted for increased 
invasiveness, but not migratory properties, of the PB 
keratinocytes (Fig. 6G, G’). Finally, the reduction of p63 
levels also affected the expression of several miRNAs 
(Fig. 6H), in agreement with the data obtained with 
huΔNp63α-expressing 940 cells (Fig. 2I). These data 
indicated that reduced p63 expression favored EMT in PB 
keratinocytes.
We next assayed the in vivo tumorigenic properties 
of control and shp63 PB cells upon subcutaneous injection 
in nu/nu mice. No differences in tumor appearance were 
observed (Fig. 7A), although tumor growth was slightly 
faster in p63-silenced cells (Fig. 7B), despite no significant 
differences in cell cycle profiles were detected between 
PB and PBshp63 cells (Supplementary Fig. 2B). The 
subcutaneous tumors displayed undifferentiated and 
differentiated areas (denoted by arrows in Fig. 7C). 
Importantly, tumors produced by PBshp63 cells displayed 
increased undifferentiated phenotype (Fig. 7D), and 
increased muscle invasiveness (Fig. 7E, 7F, 7G). 
Immunohistochemistry analyses revealed that, in parental 
PB cell-induced tumors, many muscle-invading cells 
displayed reduced p63 expression (Fig. 7H), similarly to 
tumors produced by PBshp63 cells (Fig. 7H’).
In spite of the increased invasiveness, only one 
mice subcutaneously injected with PBshp63 cells 
displayed a small lung nodule (Fig. 7I), whereas none of 
the controls showed lung metastatic lesions (not shown). 
We thus monitored the metastatic capacity of control and 
PBshp63 cells upon intravenous injection. Similarly to 
the subcutaneously injected mice, no overt metastases 
were observed one month after the tail vein injection 
of either control or shp63 cells. Nonetheless, 4 out of 
5 mice injected with the p63-silenced cells displayed 
the presence of epithelial cell aggregates in the lung 
blood vessels (Fig. 7J). This may indicate that, although 
the downregulation of p63 favors EMT process, it is 
insufficient to promote the overt metastatic behavior of 
the PB keratinocytes due, in part, to an impairment of the 
extravasation and colonization in the lungs.
ΔNp63 expression regulates pluripotency genes
The EMT process is associated with the acquisition 
of stem cell-like properties [38], and tumors with 
increased aggressiveness also display ES-like genomic 
features [36]. Accordingly, cancer cells present some 
remarkable similarities with embryonic stem cells, 
including unlimited proliferation and self-renewal, and 
the expression of pluripotency genes, such as NANOG, 
OCT4 or SOX2 [48]. Of relevance, SOX2, OCT4 and 
NANOG are also particularly involved in squamous cell 
carcinoma malignization and progression [49–51]. More 
recently, it has been reported that p63 can also alter the iPS 
generation from adult epithelial cells [52]. Consequently, 
the altered metastatic behavior produced by ΔNp63 could 
also be related to the expression of pluripotency genes. 
Figure 4: huΔNp63α expression is downregulated during spontaneous metastasis development. A, A’. Representative 
immunohistochemistry image showing p63 expression in subcutaneous tumors produced by the injection of huΔNp63α 940 cells  
B, B’. Representative immunohistochemistry images showing p63 expression in subcutaneous tumors produced by the injection of 940 cells 
C. Summary of qRT-PCR determination of huΔNp63α expression upon transduction with GFP or ΔNp63α coding lentiviruses cells, and in 
the tumors and lung metastases after subcutaneous injection of the cells. Bars = 150 μm
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We thus analyzed whether these genes were affected 
by the forced expression of huΔNp63α in 940 cells, or 
the reduced expression mediated by shRNA lentiviral 
constructs in PB keratinocytes. We observed that, in 940 
cells (Fig. 8A), the expression of huΔNp63α produced a 
significant decrease in Myc, Oct4 and Nanog genes. In 
agreement, the reduced expression of p63 was correlated 
with increased expression of all these genes in PB cells 
(Fig. 8B). These data revealed that, besides opposing to 
EMT process, p63 expression may also reduce the stem 
cell-like properties of p53-deficient mouse keratinocytes, 
thus probably contributing to the increased malignancy.
Figure 5: Expression of huΔNp63α decreases experimental metastasis development. A, A’. Representative images of H&E 
stained lung lobule sections showing the presence of metastatic nodules upon tail vein injection of 940 cells upon transduction with ΔNp63α 
(A) or GFP (A’) coding lentiviruses. Bar = 0.5 cm B–D. Summary of lung metastasis incidence (B), number of metastatic nodules per lung 
lobule (C) and lung area covered by metastatic nodules (D), observed in mice injected into the tail vein with 940 or huΔNp63α cells and 
sacrificed one month after injection. **denotes a p value < 0.01 E. Representative immunohistochemistry image showing p63 expression 
in a lung metastasis produced by the tail vein injection of huΔNp63α 940 cells. Bar = 250 μm.
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Figure 6: Knock down of p63 promotes a partial EMT process in PB transformed keratinocytes. A, B. Determination of 
p63 expression by immunoblot (A) or qRT-PCR (B) in parental PB cells and PB cells transduced with lentiviral constructs coding for two 
different shRNAs against mouse Trp63 gene. C–D’ Representative immunofluorescence images of PB (C, D) and PBshp63 cells (C’, D’) 
showing in red the expression and localization of p63 (C, C’) and E-Cadherin (D, D’) and in green keratin K5. Bar = 20 μm. E. Immunoblot 
showing the expression of the quoted proteins in PB and PBshp63 cells. F. Determination of the expression of transcription factors involved 
in EMT processes, as assessed by qRT-PCR analyses, in PB and PBshp63 cells. G G’. Determination of migratory (G) and invasive (G’) 
properties of PB and PBshp63 cells. H. Determination of the expression of miRNAs involved in EMT processes, as assessed by qRT-PCR 
analyses, in PB and PBshp63 cells. Data in F and H came from at least quadruplicated experiments. *denotes p value < 0.05, **denotes 
p value < 0.01
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Figure 7: Knock down of p63 promotes tumor dedifferentiation and invasiveness. A. Tumor incidence upon subcutaneous 
injection of PB (black line) or PBshp63 cells (red line) determined by Kaplan Meyer curves. p value was determined by log rank test. 
B. Tumor growth of subcutaneously injected PB (open squares) or PBshp63 (red squares) cells. p Value was determined by 2Way ANOVA 
followed by Bonferroni post test. *denotes p value < 0.05, **denotes p value < 0.01. C. Representative image of H&E stained subcutaneous 
tumor produced by the injection of PBshp63 cells showing the presence of undifferentiated and differentiated areas (denoted by arrows). 
Bar = 250 μm. D, E. Summary of differentiation status (D) and subcutaneous muscle invasion (E) of the subcutaneous tumors (n = 5 for 
each group) produced by the injection of PBshp63 cells. F, G. Representative images of H&E stained subcutaneous tumor produced 
by the injection of PB (F) or PBshp63 (G) cells showing the subcutaneous muscle layer invasion (denoted by arrows). Bar = 150 μm. 
H, H’. Representative immunohistochemistry images showing the expression of p63 in the muscle invasive cells of the subcutaneous 
tumors produced by the injection of PB (H) or PBshp63 (H’) cells. Bar = 150 μm. I. Metastatic nodule (denoted by arrow) observed upon 
tumor induction by subcutaneous injection of PBshp63 cells. Inset shows a higher magnification of the metastatic nodule. Bar = 250 μm. 
J. Representative image of H&E stained lung section showing the presence of malignant epithelial cell aggregate (denoted by arrow) in a 
lung blood vessel. Inset shows a higher magnification of the epithelial cell aggregate. Bar = 150 μm.
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DISCUSSION
The frequent amplification and overexpression of 
ΔNp63 in multiple epithelial cancers, have led to a general 
assumption that this protein behaves as an oncogene [12]. 
In agreement with this, ΔNp63 may repress oncogene-
induced senescence [15]. However, it has also been 
reported that reduction of p63 expression levels favors 
EMT and metastasis [20, 21, 53], and in aggressive 
invasive epithelial tumors ΔNp63 is down regulated, 
suggesting that p63 may play potential roles as metastasis 
suppressor [16–18]. Here we provide further evidence of 
this function in the context of p53-deficiency (spontaneous 
tumors in Trp53ΔEpi mice and 940 cells) or Trp53 mutation 
(PB cells).
The deficiency in p53 confers increased 
susceptibility to multiple spontaneous tumor development. 
However, based on mouse KO models [54], it has been 
assumed that complete loss of function of p53 is not prone 
to metastasis. In spite of this assumption, the reduced 
expression of other p53 family members, p63 and p73, 
produced higher tumor burden and metastatic potential 
compared to heterozygous deficient p53 mice [26], thus 
offering the first evidence suggesting that the reduction 
of p63 confers metastatic potential to transformed p53-
deficient cells. Our present data reinforce this finding and 
provide possible mechanistic explanations for this role of 
p63 as metastasis modulator.
Tumor metastasis is the major cause of mortality 
of human cancers. In epithelial tumors, metastasis is 
associated with the loss of epithelial characteristics and 
the acquisition of mesenchymal properties by a genetically 
controlled process named epithelial mesenchymal 
transition (EMT), which is also essential during embryonic 
development [55, 56]. These facts have posed tremendous 
efforts to understand the molecular mechanism controlling 
EMT in order to find possible therapeutic agents that impair 
metastatic growth of the tumors. A number of master genes 
controlling EMT in tumors have been identified [56]. We 
have previously shown that spontaneous skin tumors 
Figure 8: Altered p63 expression promotes altered expression of stemness factors. A, B. Summary of qRT-PCR determination 
of the levels of the quoted genes in 940 cells traduced with GFP or ΔNp63α (A), and in PB or PBshp63 cells (B) Data came from at least 
three independent experiments. *denotes p value < 0.05, **denotes p value < 0.01 by Mann Whitney t Test.
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caused by the epidermal-specific deficiency in Trp53 (or 
simultaneous Rb1 and Trp53 [32]) rapidly undergo EMT 
process and frequently metastatize to the lungs [37]. 
This process is accompanied by the induction of various 
EMT-inducing transcription factors and deregulated 
expression of various miRNAs [37]. Here we show that the 
transcriptional downregulation of ΔNp63 is an early event 
during tumor development in the context of p53 deficiency. 
Moreover, ΔNp63 expression is regained in lung metastasis 
outgrowths, indicating that the observed downregulation 
of ΔNp63 is not attributable to gene loss, but rather 
gene silencing. In addition, the re-expression of ΔNp63 
observed in lung metastasis, where the opposite process to 
EMT, the mesenchymal-epithelial transition, takes place, 
also suggests that ΔNp63 may play a role in this process. In 
agreement, the reduced p63 expression in PB keratinocytes 
produces impaired lung colonization, even when epithelial 
cell aggregates are commonly observed in the lung blood 
vessels. However, the absence of p63 expression in the 
metastatic nodules generated by huΔNp63α-transduced 
940 cells argues against this possible strict requirement. 
Also, it is conceivable that the absence of real metastatic 
nodules in PBshp63 cells could be related to a distinct 
pattern of p63 isoforms expressed compared to parental 
or huΔNp63α-transduced 940 cells, which may interact 
with different regulators [57], or the intrinsic differences 
in Trp53 gene status (deleted in 940 and point mutated in 
PB cells), which may alter the metastatic behavior [27, 58]. 
In this regard, it has been demonstrated that TGFβ-induced 
malignant cell responses are repressed by p63, although 
the possible specific involvement of p63 isoforms 
(ΔN or TA) has not be determined, and point mutated 
Trp53, but not p53 silencing, contributes to surpass such 
inhibition [27]. Consequently, the possible involvement of 
p63 re-expression in mesenchymal-epithelial transition, 
and the possible differential involvement of p63 isoforms 
in the context of mutated or ablated p53, would be the 
subject of future research.
The potential roles of ΔNp63 preventing EMT 
are reinforced by the observed downregulation of EMT-
mediating transcription factors, such as Snail, Twist, 
Zeb1, Zeb2 and FoxC2 upon expression of huΔNp63α 
in 940 cells; whereas p63 silencing in PB cells caused 
their increased expression (with the exception of Zeb2). 
Interestingly, the reduced metastatic behavior observed 
upon expression of huΔNp63α in 940 cells strongly suggests 
that the elucidation of the possible mechanisms leading 
to p63 silencing (Supplementary Fig. 1D), could become 
interesting strategies to prevent metastatic spreading of 
epithelial cancers characterized by loss of TP53.
The ΔNp63 protein is able to directly modulate 
transcription in a positive and negative manner, and an 
extremely wide number of transcripts have been found 
to be under p63 regulation [25, 59]. Indeed, ChIP-Seq 
approaches have identified the binding of p63 to over 
7000 genes [20, 60, 61] and only a subset of these sites are 
bound by p53 in response to DNA damage [60]. A careful 
analysis of these ChIP-seq data revealed that p63 does not 
bind to any of the above mentioned transcription factors 
mediating EMT [60], thus indicating that the observed 
deregulation is probably indirect.
Among the factors that are known to modulate 
the expression of these transcription factors, different 
miRNAs have emerged as key elements [41, 62]. In this 
regard, we have also reported that metastatic spreading 
of p53-deficent epidermal tumors is associated with 
specific deregulation of various miRNAs [37], and ChIP-
seq data identified multiple miRNAs as targets for p63 
regulation [20, 60].
In the present study we show that the experimental 
deregulation of p63 levels promoted altered expression of 
various miRNA previously involved in EMT and tumor 
metastasis, including miR-21, miR-34a, miR-200a, miR-
200b, miR-203, miR19a and miR205. Of note, several 
of these miRNAs have been identified in ChIP-seq 
experiments and display binding sites for p53 (miR-21, 
miR34a), p63 (miR-200a, miR-200b) or both (miR-205) 
[20, 60]. Importantly, many of these miRNAs can target 
various transcription factors modulating EMT and whose 
expression is affected by p63 levels. Nonetheless, other 
possible mechanisms cannot be discarded at present. 
For instance, the altered expression of p63 isoforms can 
induce a metabolic rewiring in tumor cells [21, 63], and 
oxidative metabolism could be a critical suppressor of 
metastasis [64]. Future genomics studies may provide 
new mechanistic insights about the genes and miRNAs 
regulated by p63 and the molecular mechanisms 
underlying the observed functions.
There is wide evidence that the EMT process leads 
to the acquisition of embryonic stem cell-like features 
in various human tumors [36, 62, 65, 66]. Moreover, 
the transcriptome analysis of spontaneous skin tumors 
of Trp53ΔEpi mice also revealed a significant overlap 
with embryonic stem cell like gene signatures [34]. 
More recently it has been reported that ΔNp63-deficient 
keratinocytes display increased sensitivity to cell 
reprogramming to pluripotency by Yamanaka factors [52]. 
Importantly, most if not all of these factors are also 
associated with increased malignancy in squamous cell 
carcinoma [49–51]. We thus investigated whether altered 
p63 levels could induce changes in transcription factors 
mediating reprogramming to pluripotency. We found 
that partial depletion of ΔNp63 is sufficient to induce the 
expression of Myc, Sox2, Oct4 and Nanog. Importantly, 
although none of these factors are directly bound by p63, 
they display post-transcriptional regulation by various 
miRNAs identified as targets of p63 [52]. Further, we 
have recently observed that overexpression of Nanog in 
transgenic mouse skin contributes to EMT by directly 
modulating the expression of Zeb2, Twist1 and miR-21 [51].
Collectively, our data reinforce the possible role 
of p63 as metastasis suppressor in the context of p53 
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deficiency, through the regulation of various miRNAs and 
transcription factors that modulate the EMT processes.
MATERIALS AND METHODS
Mice and cell lines
Mouse model lacking Rb1 and Trp53, or Trp53 
alone, in the basal layer of the epidermis have been 
previously described [32]. The 940, COCA and PB 
keratinocytes have been previously described [37, 42, 46]. 
To monitor in vitro migration and invasion a previously 
reported protocol was followed [37]. In vivo xenografts 
experiments are detailed in Supplementary Information. 
All the animal experiments were approved by the 
Animal Ethical Committee (CEEA) and conducted in 
compliance with Centro de Investigaciones Energéticas, 
Medioambientales y Tecnológicas (CIEMAT) guidelines.
Lentivirus construction
The sequence encoding for the human ΔNp63 gene 
was obtained by XbaI/XhoI digestion of the ΔNp63α-
FLAG vector (Adgene #26979) and inserted into de 
NheI/XhoI sites of the pL105iGFP backbone lentiviral 
vector (kindly provided by Dr. R. Murillas). Lentivirus 
production is detailed in Supplementary Information. 
For the generation of PBshp63, PB cells were transduced 
using pLKO.1 Mission Lentiviral system (Sigma, 
TRCN0000416977 and TRCN0000423330, sequences 
are provided in Supplementary Table 2) following 
manufacturer’s recommendations. A control of pLKO.1 
lentivirus containing an sh sequence that targets no known 
mammalian genes was used. Upon infection, clones were 
selected by puromycin resistance (Sigma, 20 μg/ml) for 
2 weeks.
Quantitative RT-PCR and immunoblotting
Total RNA was isolated from mouse tissue and 
culture cells and as previously described [37, 67–69]. The 
qRT-PCR procedures for genes and miRNAs are detailed in 
Supplementary Materials and Methods and Supplementary 
Table 1.Total RNA was isolated from mouse tissue and 
culture cells and as previously described [37, 67–69]. The 
qRT-PCR procedures for genes and miRNAs are detailed 
in Supplementary Information. For immunoblots, protein 
extracts were obtained and processed as described [37]. 
Detailed protocols and antibodies used are provided in the 
Supplementary information.
Immunohistochemistry and immunofluorescence
Samples were fixed in 4% PBS-buffered formalin 
or 70% ethanol, embedded in paraffin wax and sectioned 
(5 μm). Cells were grown in glass coverslips and were 
fixed in cold methanol/acetone for 10 min [70, 71]. 
Immunohistochemistry and Immunofluorescence were 
performed using previously described standard protocols 
[32, 37]. Antibodies used are detailed in Supplementary 
Information.
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